Cyclic guanosine monophosphate (cGMP) is a second messenger molecule that transduces nitric-oxide-and natriuretic-peptide-coupled signalling, stimulating phosphorylation changes by protein kinase G. Enhancing cGMP synthesis or blocking its degradation by phosphodiesterase type 5A (PDE5A) protects against cardiovascular disease 1,2 . However, cGMP stimulation alone is limited by counteradaptions including PDE upregulation 3 . Furthermore, although PDE5A regulates nitric-oxide-generated cGMP 4,5 , nitric oxide signalling is often depressed by heart disease 6 . PDEs controlling natriuretic-peptide-coupled cGMP remain uncertain. Here we show that cGMP-selective PDE9A (refs 7, 8) is expressed in the mammalian heart, including humans, and is upregulated by hypertrophy and cardiac failure. PDE9A regulates natriuretic-peptide-rather than nitric-oxide-stimulated cGMP in heart myocytes and muscle, and its genetic or selective pharmacological inhibition protects against pathological responses to neurohormones, and sustained pressureoverload stress. PDE9A inhibition reverses pre-established heart disease independent of nitric oxide synthase (NOS) activity, whereas PDE5A inhibition requires active NOS. Transcription factor activation and phosphoproteome analyses of myocytes with each PDE selectively inhibited reveals substantial differential targeting, with phosphorylation changes from PDE5A inhibition being more sensitive to NOS activation. Thus, unlike PDE5A, PDE9A can regulate cGMP signalling independent of the nitric oxide pathway, and its role in stress-induced heart disease suggests potential as a therapeutic target.
a, PDE9A in neonatal and adult cardiomyocytes; gene silencing as negative controls (scale bar, 20 mm). b, Pde9a gene expression in RNCMs with phenylephrine (PE) or adult myocytes/heart (mouse) after TAC. *P , 0.01 vs. control. Ctrl, control; KO, knockout. c, Immunoblot/immunostaining of PDE9A from human dilated cardiomyopathy (DCM) and non-failing (NF) myocardium (scale bar, 200 mm). d, e, PDE9A expression (d) and activity (e) in NF and DCM. f, PDE9A protein expression in human myocardium for NF, HFPEF and aortic stenosis (AS). *P , 0.0001, **P , 0.05 vs. non-failing; ***P , 0.0001 vs. AS and DCM. g-i, Co-localization of cardiac troponin T (cTnT) and PDE9A in human DCM myocardium. j-k, In situ hybridization of PDE9A in human NF and DCM myocardium. Data are mean 6 s.e.m. and biological replicates are indicated. overload) stimulation (Fig. 1b ). Increased PDE9A protein expression and cGMP-esterase activity is found in left ventricular myocardium from humans with heart failure and depressed function ( Fig. 1c -e, Extended Data Fig. 2b , c and Extended Data Table 1 ). Protein expression also increases in human left ventricular hypertrophy from aortic stenosis (pressure overload) and most notably in heart failure with preserved ejection fraction (HFPEF, Fig. 1f ), a prevalent form of heart failure wherein contractile function appears normal despite symptoms 12 . Human PDE9A expression primarily localizes to myocytes based on co-localization with troponin-T ( Fig. 1g -i) and in situ hybridization staining (Fig. 1j, k) . Whereas PDE5A is expressed in fibroblasts 9 , PDE9A is essentially undetectable in isolated human fibroblasts (qPCR threshold cycle 5 39).
PDE9A upregulation by heart disease suggested its inhibition might blunt pathological stress responses. To test this, RNCMs and adult myocytes were stimulated with phenylephrine or endothelin-1 (ET-1), increasing protein synthesis and hypertrophic fetal gene (Nppa, Nppb) expression. Co-incubation with a selective PDE9A antagonist (PF-04449613 (PF-9613), 5 mM, Extended Data Fig. 3a for selectivity of PDE9A versus PDE5A), or Pde9a gene silencing/deletion ( Fig. 2a , b (top)) reversed these changes. Cells lacking PDE9A were unaffected by PF-9613, confirming the drug's selectivity ( Fig. 2a ). Similar results were obtained with PF-04447943, another PDE9A inhibitor now used in human trials (NCT00930059, Extended Data Fig. 3b ). Anti-hypertrophic effects of PDE9A inhibition required activation of PKG, as they were blocked by PKG inhibitor DT3 (Fig. 2b (bottom) and Extended Data Fig. 3c ).
Both PDE5A and PDE9A regulate cGMP-PKG activity; therefore we tested if this regulation is redundant or targets different cGMP pools. Gene silencing of Pde9a in RNCMs had no effect on cGMP augmentation from a nitric oxide donor (diethylamine nitric oxide (DEANO), 1 mM) but enhanced cGMP ( Fig. 2c ) and PKG activity (Extended Data Fig. 4a ) triggered by natriuretic peptide type A (ANP (also known as NPPA), 1 mM). Adult myocytes exposed to PF-9613 also augmented cGMP only with ANP stimulation ( Fig. 2d ; Pde9a 2/2 cells were negative controls). We also measured intracellular cGMP generation in adult myocytes expressing the cGMP-fluorescent sensor, FlincG 13 ( Fig. 2e ). 
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ANP-stimulated cGMP increased more after PF-9613 in control cells, but not in those lacking PDE9A ( Fig. 2f ). By contrast, PF-9613 did not alter cGMP stimulated by DEANO, whereas the latter increased with PDE5A-inhibition (sildenafil (SIL), 1 mM, Fig. 2g ). Neither SIL nor PDE5A-siRNA altered ANP-stimulated cGMP (Extended Data Fig. 4b , c). Pre-incubation with soluble guanylate cyclase (sGC) inhibitor ODQ (10 mM, 1H- [1, 2, 4] oxadiazolo[4,3,-a]quinoxalin-1-one) had no effect on cGMP stimulated by ANP or ANP plus PF9613, but fully blocked the rise from DEANO or DEANO 1 SIL ( Fig. 2h ). Lastly, RNCMs with silenced Pde5a, Pde9a, or both were incubated with the NOS-inhibitor L-NAME (1 mM). Phenylephrine-stimulated hypertrophic genes were suppressed only if PDE9A was silenced ( Fig. 2i ). Thus, opposite to PDE5A, PDE9A hydrolyses cGMP coupled to natriuretic peptide but not nitric oxide stimulation.
We hypothesized that disparate cGMP targeting is related to intracellular localization and thus PDE compartmentation. Confocal immunohistochemistry confirmed this, revealing PDE5A but not PDE9A co-localization with a-actinin at the Z-disk, and PDE9A but not PDE5A co-localization with T-tubular membranes (sarcoplasmic reticulum ATPase-2a) (Extended Data Fig. 5 ). Interestingly, natriuretic peptide receptor type A also displays a striation pattern in myocytes 14 .
To test if PDE9A contributes to maladaptive hypertrophy and heart remodelling in vivo, Pde9a 2/2 mice were exposed to sustained pressure overload. Their hearts developed less dilation and dysfunction, had reduced heart and lung weights, interstitial fibrosis, and myocyte hypertrophy versus TAC (transverse aortic constriction) littermate controls ( Fig. 3a-d) . Myocardial cGMP increased more in Pde9a 2/2 hearts (Fig. 3e ), and this was accompanied by suppression of pathological genes including connective tissue growth factor, fibronectin and transient receptor potential canonical channel type 6 ( Fig. 3f ). The latter signals upstream of calcineurin-NFAT, transduces myofibroblast transformation and hypertrophy 15 , and is directly inhibited by PKG 16, 17 . Cyclic GMP can also suppress cAMP by activating PDE2 18 to blunt hypertrophy and fibrosis; however cAMP rose similarly in both groups after TAC (Extended Data Fig. 6 ).
The clinically relevant question is whether inhibition of PDE9A reverses pre-established hypertrophy/dysfunction, and whether this is differentiable from the protection afforded by PDE5A inhibition. To address this, C57BL/6J mice were subjected to severe TAC to rapidly induce chamber dilation, dysfunction and hypertrophy. On day 8, mice were divided into three groups: PF-9613, SIL or vehicle, and treated for an additional 4 weeks while maintaining TAC. Oral PF-9613 itself had no effect on blood pressure or heart function (Extended Data Fig. 7 ). To test if cGMP targeting by PDE9A differed from PDE5A in vivo, the experiment was repeated adding the NOS inhibitor L-NAME to the drinking water.
All groups developed marked chamber dysfunction, dilation, and hypertrophy after 1 week of TAC (pre-treatment; Fig. 4a, b ). In mice that did not receive L-NAME, inhibiting either PDE reversed changes to near sham-control levels and lowered post-mortem left ventricular mass, lung weight and abnormal molecular signatures (Extended Data Fig. 8 ). However, in L-NAME-treated mice, only PDE9A inhibition was effective ( Fig. 4a, b ). Blocking either PDE increased myocardial cGMP in L-NAME 2 -TAC but only PDE9A inhibition did so in L-NAME 1 -TAC mice ( Fig. 4c ). L-NAME prevented PKG activation by SIL but not PF-9613 ( Fig. 4d ). In vitro PKG activity in PDE9A-treated myocardium was itself little altered. This parallels reported data with natriuretic peptide stimulation, but differs from increases seen with PDE5A inhibition 5 .
To explore differential signalling from each PDE inhibitor further, RNCMs were infected with luciferase reporter plasmids to assess the 
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activation of transcription factors known to regulate cardiac growth/ hypertrophy and survival. NFAT, MEF2 and CREB all increased with phenylephrine stimulation. NFAT declined with PDE5 or PDE9 inhibition, consistent with results for TRPC6 ( Fig. 4e and Extended Data Fig. 8 ) and studies showing that both natriuretic peptide and nitric oxide stimulation block this pathway 16, 17 . MEF2 only declined with PDE5A-I while both GATA4 and CREB rose only with PDE9A-I (Fig. 4e ). The latter two are linked to natriuretic peptide /cGMP signalling, enhanced survival and adaptive myocardial stress responses 19, 20 .
Lastly, we performed unbiased proteomic analysis to detect serine/ threonine phosphorylation increases in myocyte proteins altered by PDE9A-I or PDE5A-I, with or without concomitant L-NAME. The majority (85%) of phosphorylated amino acid residues were modified by one or the other PDE inhibitor and the rest by both ( Fig. 4f and Supplementary Table 1 ). Of these residues, L-NAME reduced 21% of those specific to PDE5A-I versus 5.2% to PDE9A-I (red symbols, P , 0.02), supporting targeting of PDE9A to non-nitric-oxide-dependent cGMP (Supplementary Table 2 ).
The efficacy of inhibiting a cGMP-PDE to counter myocardial responses to pathological stress requires having sufficient cGMP synthesized and PDE expressed, and pathogenic signalling suppressible by PKG. Though prior work indicated PDE5A might fulfil these criteria, its preferred targeting to NOS-dependent cGMP is a potential limitation, as this pool is often depressed in cardiovascular disease. We have now identified PDE9A-I as an alternative that, unlike PDE5A-I, remains effective even when NOS-dependent cGMP synthesis is suppressed. This non-redundant function is consistent with intracellular compartmentation 21 . The revelation that PDE9A serves as a natriuretic-peptide-cGMP-targeted PDE is important as this source of cGMP often rises in heart disease, whereas the NOS-derived pool declines. As with PDE5A, there are multiple downstream targets stemming from PDE9A regulation that collectively impact myocardial biology and disease. The current data identifies transcriptional controllers and protein substrates, setting the stage for future work.
The observation of heightened PDE9A expression in human heart failure, particularly HFPEF is exciting. Morbidity and mortality from inhibition reverses pre-established hypertrophy/dysfunction in a NOS-independent manner. a, M-mode echocardiograms from mice 6 L-NAME exposed to 5-week TAC 6 PDE5A or PDE9A inhibition starting one week after TAC. b, PF-9613 and SIL reversed cardiac dysfunction from TAC in L-NAME 2 mice, but only PF-9613 was effective in L-NAME 1 mice. 
LETTER RESEARCH
HFPEF is high and with still no effective therapies this remains a major unmet medical need worldwide 12 . While there is considerable enthusiasm for cGMP-PKG-targeted treatment for this disease 22 , recent data from a multicentre clinical trial using PDE5A-I was disappointing 23 . Among potential reasons are a lack of PDE5A upregulation and low myocardial cGMP attributed to depressed nitric oxide signalling 24 . Our results suggest PDE9A-I as an attractive alternative. The recent success of a combined angiotensin receptor blocker and neprilysin inhibitor 25 (the latter blunting natriuretic peptide proteolysis) that is being tested in HFPEF (NCT01920711), and advances in synthetic natriuretic peptide therapies 26 offer opportunities for combined treatment. PDE9A inhibitors appear well tolerated in humans and are being studied for neurocognitive disease (https://clinicaltrials.gov/ct2/show/NCT00930059). The current results support exploring these agents as new avenues for treatment of the heart, and potentially other organs in which PDE9A and the natriuretic peptide signalling system have a role.
METHODS
Human myocardial tissue. Procurement of human myocardial tissue was performed under protocols approved by Institutional Review Boards at the University of Pennsylvania (Pennsylvania, USA), Johns Hopkins University (Maryland, USA) and VU University Medical Center, (Amsterdam, The Netherlands) and its coordinated affiliated centres 24 and consent for biopsy procedures or use of explanted tissues prospectively obtained in all cases. Explant dilated non-ischaemic failing human hearts were procured at the time of orthotopic heart transplantation at the Hospital of University of Pennsylvania. Non-failing hearts were obtained at the time of organ donation from cadaveric donors. In all cases, hearts were arrested in situ using ice-cold cardioplegia solution, transported on wet ice, and flash frozen in liquid nitrogen within 4 hours of explantation. All samples were full-thickness biopsies obtained from the free wall of the left ventricle. HFPEF patients were referred for cardiac catheterization and left ventricular endomyocardial biopsy because of clinical suspicion of restrictive cardiomyopathy. Left ventricular biopsies were procured using femoral artery access and a long bioptome. Diagnostic criteria and clinical characteristics of the HFPEF and aortic stenosis patients have been previously reported 24 . Control samples for these studies were obtained from explanted unused donor hearts. Pde9a knockout mouse. All protocols involving animals followed US National Institutes of Health guidelines and were approved by the animal and care use committee of the Johns Hopkins Medical Institutions. Pde9a global knockout (Pde9a 2/2 ) mice were developed by Pfizer Inc. The model replaced exon 12 in the catalytic domain of Pde9a with a lacZ-neomycin cassette (see Extended Data Fig. 1 ). Mice did not express any splice variants as they all share this sequence. Pde9a 2/2 mice were born in normal Mendelian ratios, and had no evident physiological or behavioural abnormalities (Supplementary Table 3 ). Expression of alternative cGMPtargeting PDEs, PDE1A and PDE5A were not significantly different in Pde9a 2/2 versus littermate control hearts (Extended Data Fig. 9 ).
Transverse aortic constriction and chronic drug studies. Pressure overload was performed by surgical placement of suture around the transverse aorta sized to a 27G needle, as described previously 1 . For chronic drug treatment studies, size-, ageand sex-matched (male) C57BL/6J mice (Jackson Labs) were randomized to receive vehicle, PF-9613 (30 mg kg 21 twice a day by oral gavage), or sildenafil (200 mg kg 21 per day with Bioserv soft diet). The mean free plasma concentration of PF-9613 was 77 nM, (peak of 1.5 mM at 30 min, t 1/2 5 1.2 h) within the selective range, while sildenafil yielded 30 nM 1 , also in the selective range. Mice were subjected to TAC or a sham operation. Mice were euthanized at 5 weeks for tissue analysis. This protocol was then repeated in mice administered L-NAME (1 mg ml 21 in drinking water) initiated one week before TAC, and continued for the full 5-week TAC. Tissue histology and echocardiography followed reported methods 27 . For these studies, in vivo analysis and post-mortem myocardial analysis were performed blinded as to experimental group. In vivo Pde9a 2/2 analysis included all animals studied. For the drug intervention study, which was designed to test reversal of heart disease established after one week of TAC, animals dying in the first week (before drug assignment) or who failed to develop disease after TAC (likely related to inadequate constriction) were excluded from analysis. Chronic PF-9613 had no effect on cardiac function or systemic pressures (for example, no evidence of arterial vasodilation) in shams (Extended Data Fig. 7 ). There was also no systemic vasodilation from drug treatment in TAC hearts (for example, systemic resistance was: vehicle, 11.5 6 1; PF-9613, 10.6 6 2 mm Hg per ml per min; P . 0.5).
PDE9A inhibitors: PF-04449613 and PF-04447943 and siRNA vectors. The structure and pharmacology of PF-04449613 and PF-04447943 have been reported 10, 28 . We performed a dose-ranging study for PDE9A and PDE5A selectivity using a fluorescent polarization assay 1 (Molecular Devices) (Extended Data Fig. 3a ). This identified 5 mM PF-04449613 inhibited 70% of PDE9A without altering PDE5A activity, whereas 1 mM sildenafil blocked more than 70% of PDE5A activity with no effect on PDE9A. These concentrations were used in the subsequent cell culture studies. For gene silencing, we used targeted siRNA (PDE9A, L-098890-02; PDE5A, L-093210-02; control, D-001810-10; on-target siRNA smart pool, Dharmacon) or scrambled controls, achieving 70-80% knockdown (Extended Data Fig. 1c ). Isolated myocyte hypertrophy and immunohistochemistry. Cell isolation methods for both neonatal and adult myocytes have been reported previously 27 . For adult cell studies, the isolation process itself produces variance in the absolute agonist response observed. Thus, quantitative response comparisons are best considered within a given cell type (for example, control or Pde9a 2/2 ). RNCMs were isolated from 1 to 2-day-old Sprague-Dawley rats and cultured for 2 days before study, while adult mouse myocytes were studied in primary culture for no more than 24 h. For immunohistochemistry, myocytes were plated on laminin-coated imaging dishes, fixed with 50% methanol and 50% acetone, permeabilized with 0.1% saponin in PBS, and blocked in 10% bovine serum albumin in PBS. Cells were then incubated overnight with primary antibodies at 4 uC (rabbit anti-PDE9A (using human peptide), gift of L. Jaffe, 1:100 or 1:50 dilution for wild type and knockout, respectively; rabbit anti-PDE5 (1:250, Cell Signaling); mouse anti-SERCA2 (1:250, Abcam); mouse anti-a actinin (1:500, Sigma)); then with secondary antibodies for 1 h at room temperature (Alexa Fluor 488-or Alexa Fluor 546-conjugated; Invitrogen); then imaged on an inverted epifluorescent microscope with argon-krypton laser confocal scanning (Zeiss, UltraView; Perkin Elmer Life Science Inc.).
Human heart immunostaining and in situ hybridization. Sectioned human heart tissues were dehydrated with PBS in buffer containing 10 mM sodium citrate, 0.05% Tween 20 at pH 6.0. Sections were blocked for 1 h at room temperature in PBS with 0.1% bovine serum albumin and 0.1% Tween-20) followed by incubation with PDE9A (1:200) or cardiac TnT antibody (1:100, Thermo).
In situ hybridization with a digoxigenin (DIG)-labelled PDE9A probe was performed as described previously 29 . We generated an anti-sense RNA probe to human PDE9A using a partial sequence of human PDE9A, flanked with forward (59-TG TCCTAGAGAAACGCGTGG-39) and reverse (59-GGTGACAGGGTTGATGCT GA-39) primers, amplified by PCR, and ligated into pGEM-T-easy vector (Promega). Anti-sense RNA probe labelled with DIG was prepared using the RNA labelling kit (Roche). Molecular analyses. PDE and PKG activity, and cAMP and cGMP levels were determined as previously described 1 . Quantitative PCR was used to assess RNA expression using standard procedures. PCR primers were: TaqMan primers used:
For SYBR primers used: rat Nppa (forward 59-ATACAGTGCGGTGTCCAACACAG A-39, reverse 59-TGACCTCATCTT CTACCGGCATCT-39), rat Nppb (forward 59-ATGCAGAAGCTGCTGGAG CTGATA-39, reverse 59-CTTCTGCCCAAAG CAGCTTGAACT-39), rat Gapdh (forward 59-GACATGCCGCCTGGAGAAAC-39, reverse 59-AGCCCAGGATGCCCTTTAGT-39), rat Pde5a (forward 59-AACTC GTGGCAGCCGAATTCTTTG-39, reverse 59-TGTTCATTAGATCAGCGGGCT CCA-39), and rat Pde9a (forward 59-TACGGAAGCCCACCTTTGATGTCT-39, reverse 59-TTGGGTTGATGCTGAAGTCCCTGA-39). All PCR samples were run in duplicate and normalized to GAPDH. Specificity of the SYBR green assays was confirmed by dissociation curve analysis.
Protein electrophoresis and immunoblot assays followed standard procedures, using lysis buffer (Cell Signaling) with protease inhibitor PMSF (1 mM), and run on NuPAGE 4 to 12% gel (Invitrogen). Membranes were probed for human anti-PDE9A (1:1,000), mouse anti-GAPDH or human anti-actin (1:10,000, Cell Signaling). Quantitation used fluorescence detection (Odyssey, Licor, and Odyssey Application Software 3.0). For human left ventricular biopsy tissue analysis, samples were applied at 25 mg (dry weight), and probed with primary antibody (Millipore, ABN32, dilution 1:1,000), and visualized using secondary horseradish-peroxidase-labelled, goat-anti-rabbit/mouse antibody (dilution 1:1,000; DakoCytomation) and enhanced chemiluminescence (ECL western blotting detection, Amersham Biosciences). Signals were normalized to actin (dilution 1:1,000; clone KJ43A; Sigma) stained on the same blots. Leucine incorporation assays were performed as described previously 16 Real-time myocyte cGMP analysis. RNCMs plated on gelatin-coated 35-mm glass-bottom culture dishes (MatTek) were incubated overnight and, at 50% confluence, exposed to adenovirus expressing FlincG 13 (courtesy of W.R.D.) at a multiplicity of infection of 10, for 24-48 h at 37 uC, 5% CO2 until a 90% transfection efficiency was achieved. Since the absolute level of expressed FlincG varied among cells, each cell was used as their own control, with stimulation protocols compared within a given cell by paired analysis. Cell imaging was performed in imaging buffer (Hank's balanced salt solution (HBSS), Mediatech, Inc.) by using a 3i spinning disk confocal system on a Zeiss microscope with SlideBook 5.0 software (Intelligent Imaging Innovations, Inc.), a 633 oil dipping objective (N.A. 1.0), and iXon ENCCD DVB camera with 1-s acquisitions and 20 ms exposure time, exciting with a solid state laser at 488 nm and collecting the emission at 510 nm at 37 uC. cGMP responses are investigated upon local application (20 to 50 ml) and subsequent diffusion of DEANO (Calbiochem), ANP (Sigma), ODQ (Sigma) and specific PDE inhibitors (Pfizer). Data are analysed by using the Slidebook software. Histology. Myocardium was fixed with 10% formaldehyde, paraffin embedded and sectioned into 4-mm slices. Masson's trichrome staining was used to visualize collagen. Quantification of fibrosis content was performed in four to six regions of each heart. For wheat germ agglutinin staining of mouse heart sections, slides were deparaffinized, rehydrated, and subjected to citrate-based heat-mediated antigen retrieval. Slides were incubated with 5 mg ml 21 Alexa Fluor 647-conjugated wheat germ agglutinin (Invitrogen) overnight at 4 uC and mounted using Prolong Gold mounting medium (Invitrogen) 27 . Myocyte cross sectional area was measured using an automated algorithm with NIH Image J 1.47i software. Image acquisition was performed on a Zeiss LSM510-META laser scanning microscope. Luciferase reporter assay. RNCMs were transfected with Nfat-luc, Creb1-luc, Gata4-luc, TK-luc (Promega) or Mef2-luc (Addgene), using Xfect reagent (Clontech) according
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to the manufacturer's protocol. After 24 h transfection, cells were stimulated with 25 mM of phenylephrine for 6 h, lysates harvested using passive lysis buffer (Promega) and luciferase activity determined using the Dual-Luciferase Reporter Assay System (Promega) and Veritas 96-well microplate luminometer (Turner Biosystems) following the manufacturer's protocol. Phosphoproteomic analysis. Samples (n 5 4 per group) were lysed in 8 M urea, 0.5% SDS with brief sonication and protein concentration determination by the BCA method. For each sample, 200 mg of total protein was digested with trypsin/ Lys-C protease mixture (Promega) according to previously published methods 30 , samples desalted on 10-mg Oasis HLB cartridges (Waters) and eluted in 300 ml of 80% acetonitrile, 5% trifluoroacetic acid and 1 M glyocolic acid, and enriched by titanium dioxide (TiO2). Enriched peptides were desalted as above but eluted in 200 ml of 80% ACN, 0.1% formic acid and dried under vacuum. Dried peptides were re-suspended in 20 ml of 0.1% FA for liquid chromatrography-tandem mass spectrometry analysis.
For each sample, 4 ml was injected in duplicate onto an EASY-nLC 1000 (mobile phase A was 0.1% FA in water and mobile phase B was 0.1% FA in ACN) connected to a Q-Exactive Plus (Thermo) equipped with a nano-electrospray ion source. All raw MS/MS data was searched using the Sorcerer 2TM-SEQUEST algorithm (Sage-N Research) using default peak extraction parameters. Post-search analysis was performed using Scaffold 4 (Proteome Software, Inc.) with protein and peptide probability thresholds set to 95% and 90%, respectively, and one peptide required for identification, and these the spectra were manually validated. Phosphosite localization was determined using Scaffold PTM version 2.1.3 and phosphosites with probabilities less than 90% were ignored. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the data set identifier PXD001585. Statistics and reproducibility. For all analyses, sample size is reported in the figure legends or figures themselves. Most in vitro studies were done with two to three sets of independent experiments. Comparisons of multiple groups were performed using either one-way or two-way ANOVA (as appropriate). If normality or equal variance tests failed, then a Kruskal-Wallis test was used. Two-group anlaysis used either a Student's t-test or a non-parametric Mann-Whitney test. Post-hoc multiple comparisons testing used either a Tukey or Dunns test. Analysis of time-dependent changes was performed by ANCOVA with repeated measures. Formal power analysis was not prospectively performed, though for variables where variance was known we could estimate sample size based on an anticipated mean effect. 
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Extended Data Figure 2 | Expression of PDE9A protein in RNCM, mouse brain and human heart. a, Immunoblot for PDE9A in neonatal cardiomyocytes transfected with either scrambled control siRNA (Sc) or Pde9a siRNA (siR), confirming the suppression of protein expression by the siRNA. A control gel for comparison was derived from brain tissue using Pde9a 2/2 mice and littermate controls. The band identified at ,60 to 65 kDa was similar in both tissues. PDE9A bands are usually identified between 55-70 kDa depending on the splice variants expressed in a given tissue and species. b, Control immunohistochemistry showing that PDE9A detected by antibody can be largely quenched (inactivated) selectively by preincubation with recombinant ligand; scale bar, 50 mm. c, Immunostaining of PDE9A from all 8 control and DCM patients; scale bar, 200 mm. There was consistent enhanced staining in DCM patients versus controls. All images were obtained at an identical level of laser illumination and have not been altered.
Extended Data Figure 3 | Selectivity of PDE9A inhibitors. a, The dose responses of recombinant PDE9A or PDE5A to a selective PDE9A inhibitor (PF-9613) and sildenafil. Data performed in triplicate at each point. A dose of 5 mM PF-9613 inhibited PDE9A effectively, but had negligible impact on PDE5A. By contrast, the PDE5A inhibitor sildenafil inhibited PDE5A by 80% at a dose of 1 mM, commonly used for cells and tissue, but had no impact on PDE9A at this dose. These doses were therefore used in our cell-based studies. b, Confirmation that an alternative PDE9A inhibitor (PF-04447943), currently being tested in humans, shows similar anti-hypertrophic effects as PF-9613 in cardiac myocytes (n 5 4 per group); *P , 0.001 vs. baseline; #P , 0.01 vs. phenylephrine. c, Inhibition of PKG activity with DT3 reverses the suppression of phenylephrine-stimulated Nppb gene expression by PF-9613. This is a companion panel to Fig. 2b , bottom. n 5 6 for basal (no drugs), n 5 8 for other groups; *P , 0.001 vs. baseline; #P , 0.01 vs. phenylephrine. Data are mean 6s.e.m.
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